Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Title
Intervention Indication Therapeutic Area Year Actions
Belantamab mafodotin for relapsed / refractory multiple myeloma – Fourth line Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2019 View  |  Download
Belantamab mafodotin for treating relapsed or refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications